This project will focus on developing novel targeted viral vectors and imaging delivery and transgene expression in tumor cells and in mouse tumor models. Based on over ten years experience developing novel vectors and therapeutic transgenes for tumor therapy, it is clear that one of the major limitations to the effectiveness of this new treatment paradigm is insufficient gene delivery to tumor cells in vivo. In order to compare and optimize different delivery strategies, it is imperative to be able to quantitatively assess vector targeting and transgene delivery in animals, and eventually in human patients. Our goals, then, are to help develop technology, which can be widely applied to a variety of vector/tumor paradigms in order to effect on-site visualization of gene therapy in vivo. Our model vector will be the plasmid-based amplicon vector, which incorporates non-coding elements of herpes simplex virus type 1 (HSV), and hence combines ease of construction, highly efficient gene delivery, and minimal inherent toxicity. These vectors will be targeted to tumor cells by incorporation of the peptide/protein ligands, which bind to tumor- enriched receptors, into the envelope of the virion. These tumor receptors are believed to have an important role in the oncogenesis of specific tumor types and hence serve both as diagnostic markers and eventual therapeutic targets. Virions will be imaged in several ways, including: 1) 111/IN-oxine labeling or genetically modifying the viral envelope protein (gC) with metallothionein known to bind 99m/Tc to image genetically modifying the viral envelope protein (gC) with metallothionein known to bind. 99m/Tc to image mass distribution; and 2) use of proteases as reporters to rapidly monitor transgene expression in cells using previously developed near infrared fluorescent imaging probes (Nature Biotech 1999; 17:375-378). We will attempt to amplify the imaging signals conferred by transgene expression by genetic amplification of the transgene within the host cell nucleus. In addition, we will try to enlarge the domain of imaging by expression of proteins which can be translocated from transduced cells through the extracellular space to surrounding cells or which will mediate fusion of transduced cells with neighboring cells. And finally, we will elicit and monitor tumor cell killing through apoptosis, as mediated by expression of ICE which induces cell suicide. In vivo imaging will play a critical part in this project to test the novel approaches. The developed vector systems may ultimately be used to follow transgene delivery and expression in patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA086355-02S1
Application #
6492311
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2001-08-07
Project End
2002-07-31
Budget Start
Budget End
Support Year
2
Fiscal Year
2001
Total Cost
$241,412
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Miller, Miles A; Weissleder, Ralph (2017) Imaging the pharmacology of nanomaterials by intravital microscopy: Toward understanding their biological behavior. Adv Drug Deliv Rev 113:61-86
Engblom, Camilla; Pfirschke, Christina; Zilionis, Rapolas et al. (2017) Osteoblasts remotely supply lung tumors with cancer-promoting SiglecFhigh neutrophils. Science 358:
Miller, Miles A; Askevold, Bjorn; Mikula, Hannes et al. (2017) Nano-palladium is a cellular catalyst for in vivo chemistry. Nat Commun 8:15906
Dubach, J Matthew; Kim, Eunha; Yang, Katherine et al. (2017) Quantitating drug-target engagement in single cells in vitro and in vivo. Nat Chem Biol 13:168-173
Vinegoni, Claudio; Fumene Feruglio, Paolo; Brand, Christian et al. (2017) Measurement of drug-target engagement in live cells by two-photon fluorescence anisotropy imaging. Nat Protoc 12:1472-1497
Iaconelli, Jonathan; Lalonde, Jasmin; Watmuff, Bradley et al. (2017) Lysine Deacetylation by HDAC6 Regulates the Kinase Activity of AKT in Human Neural Progenitor Cells. ACS Chem Biol 12:2139-2148
Arlauckas, Sean P; Garris, Christopher S; Kohler, Rainer H et al. (2017) In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci Transl Med 9:
Pucci, Ferdinando; Garris, Christopher; Lai, Charles P et al. (2016) SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions. Science 352:242-6
Roy, Jeremy; Kim, Bongki; Hill, Eric et al. (2016) Tyrosine kinase-mediated axial motility of basal cells revealed by intravital imaging. Nat Commun 7:10666
Pfirschke, Christina; Engblom, Camilla; Rickelt, Steffen et al. (2016) Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. Immunity 44:343-54

Showing the most recent 10 out of 316 publications